Last reviewed · How we verify

Immediate Release Oxycodone

University of Rochester · FDA-approved active Small molecule Quality 5/100

Immediate Release Oxycodone, marketed by the University of Rochester, holds a position in the pain management market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism for effective pain relief, supported by its current market presence. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameImmediate Release Oxycodone
Also known asMedication comparison
SponsorUniversity of Rochester
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: